Osteoporosis in HIV-infected subjects: A combined effect of highly active antiretroviral therapy and HIV itself? [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 4, 2005, Pages 503-504

  Bongiovanni, Marco ^a   Fausto, Alfonso ^b   Cicconi, Paola ^a   Menicagli, Laura ^b   Melzi, Sara ^a   Ligabo, Valentina Emanuela ^a   Cornalba, Giampaolo ^b   Bini, Teresa ^a   Sardanelli, Francesco ^b   Monforte, Antonella D'Arminio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

BONE METABOLISM; BONE NECROSIS; COMORBIDITY; CONFIDENCE INTERVAL; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; OSTEOPENIA; OSTEOPOROSIS; OUTPATIENT CARE; PATIENT CODING; PATIENT INFORMATION; PATIENT SELECTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL RATE; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 27944456434     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000184861.26733.8c     Document Type: Letter

References (10)

1. Palella FJ, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(Suppl):F51-F58.
3. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14(Suppl):F63-F67.
4. Knobel H, Guelar A, Vallecillo G, et al. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS. 2001;15:807-808.
5. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482-490.
6. Carr A, Miller J, Eisman J, et al. Osteopenia in HIV-infected men: association with asymptomatic lactic academia and lower weight pre-antiretroviral therapy. AIDS. 2001;15:703-709.
7. Bruera D, Luna N, David DO, et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17:1917-1923.
8. Konishi M, Takahashi K, Yoshimoto E, et al. Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients. AIDS. 2005;19:1240-1241.
9. Huang CJ, Muller F, Aukrust P, et al. Subnormal serum concentration of 1.25 dihydroxyvitamin D3 in HIV infection: correlation with degree of immunodeficiency and survival. J Infect Dis. 1994;169:889-893.
10. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. World Health Organ Tech Rep Ser. 1994;843:1-129.